Company: SCLXW
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0000950170-25-006777
Chunk: 94

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 424B3
Chunk 94
---
B                                  |     |                                 |       |   |     |      |        |     |            |        |   |
| Contracted R&D                          |     |                                 |   636 |   |     |      |    745 |     |            |   (109 | ) |
| Personnel                               |     |                                 |   765 |   |     |      |    677 |     |            |     88 |   |
| Other                                   |     |                                 |   362 |   |     |      |    125 |     |            |    237 |   |
| Total ELYXYB                            |     |                                 | 1,763 |   |     |      |  1,547 |     |            |    216 |   |
| Total Research and Development Expenses |     | $                               | 7,461 |   |     | $    | 10,012 |     | $          | (2,551 | ) |

Research and development expenses for the nine months ended September 30, 2024 and 2023 were $7.5 million and $10.0 million, respectively. The $2.5 million decrease was primarily attributed to reduced costs of SP-103 due to the completion of the Phase 2 clinical study and reduced development cost of SP-104.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the nine months ended September 30, 2024 and 2023 were $83.6 million and $96.1 million, respectively. The decrease of approximately $12.5 million was primarily due to a $11.1 million decrease in advisory and financing expenses, a $9.4 million decrease in legal fees, a $1.3 million decrease in insurance costs, and a $0.2 million decrease as a result of $1.4 million decrease related to allowance for credit losses that was made in March 2023 for the receivable from Sorrento offset by $1.2 million increase related to allowances for expected credit losses on accounts receivable, partially offset by a $5.3 million increase in rebate expense related to future shipments of the Additional Product (as defined below) under the Satisfaction Agreement, a $1.4 million increase in contracted services, a $0.7 million increase in marketing expenses, a $0.6 million increase in personnel expense due to an increase in headcount and a merit increase starting January 2024, a $